TPO-RAs in children with ITP are proposed as a second-line treatment over rituximab and splenectomy only for those with non-life-threatening mucosal bleeding who had not responded to first-line treatment with corticosteroids. The gene discussed is TPO; the disease is autoimmune thrombocytopenic purpura.